🧫
Tirzepatide vs Semaglutide Anti-Atherosclerotic Effects in ApoE KO Mice
active
experiment
Created: 2026-04-10T22:43:24
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-fe270634-6727-428d-b105-0f09d0bf86f2
🧫 Experiment Protocol
ValidationAtherosclerosis and diabetesApoE knockout mice with streptozotocin-induced diabetesproposed
This comprehensive animal study investigated the comparative anti-atherosclerotic properties of tirzepatide (dual GIP/GLP-1 receptor agonist) versus semaglutide (selective GLP-1 receptor agonist) in apolipoprotein E knockout mice. The experiment was designed with three distinct groups based on diabetes status and timing: early diabetes (treated from 10-22 weeks of age), late diabetes (treated from 18-30 weeks of age), and non-diabetic controls. Each group received 12 weeks of treatment with either tirzepatide, semaglutide, or saline control following streptozotocin-induced diabetes. The study assessed multiple parameters including aortic plaque formation, glycemic control, lipid profiles, and inflammatory markers. Key inflammatory mediators measured included Mcp-1, Il-6, I-cam, and Cd68. The research aimed to determine whether the vascular protective effects were dependent on metabolic improvements or involved direct arterial actions.
PRIMARY OUTCOME
Aortic plaque formation
EXPECTED OUTCOMES
Both tirzepatide and semaglutide were expected to reduce atherosclerotic plaque formation and improve metabolic parameters, with potential differences in their anti-inflammatory profiles
SUCCESS CRITERIA
Significant reduction in aortic plaque formation compared to saline control, improvement in glycemic and lipid parameters, and reduction in inflammatory mediators
PROTOCOL
ApoE knockout mice were treated with streptozotocin to induce diabetes, then divided into three groups (early diabetes 10-22 weeks, late diabetes 18-30 weeks, non-diabetic). Each group received 12 weeks of treatment with tirzepatide, semaglutide, or saline control. Assessments included plaque quantification, glycemic measurements, lipid profiling, and inflammatory marker analysis.
Source: PMID 41946762 ↗
🧫 Experiment Extras
PATHWAY
GIP/GLP-1 receptor signaling pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.